These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35662833)

  • 1. Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.
    Nirogi R; Ieni J; Goyal VK; Ravula J; Jetta S; Shinde A; Jayarajan P; Benade V; Palacharla VRC; Dogiparti DK; Jasti V; Atri A; Cummings J
    Alzheimers Dement (N Y); 2022; 8(1):e12307. PubMed ID: 35662833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study.
    Nirogi R; Goyal VK; Benade V; Subramanian R; Ravula J; Jetta S; Shinde A; Pandey SK; Jayarajan P; Jasti V; Cummings J
    Neurol Ther; 2022 Dec; 11(4):1583-1594. PubMed ID: 35908254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
    Fullerton T; Binneman B; David W; Delnomdedieu M; Kupiec J; Lockwood P; Mancuso J; Miceli J; Bell J
    Alzheimers Res Ther; 2018 Apr; 10(1):38. PubMed ID: 29622037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.
    Nirogi R; Jayarajan P; Benade V; Shinde A; Goyal VK; Jetta S; Ravula J; Abraham R; Grandhi VR; Subramanian R; Pandey SK; Badange RK; Mohammed AR; Jasti V; Ballard C; Cummings J
    Int J Geriatr Psychiatry; 2022 Oct; 37(10):. PubMed ID: 36168659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
    Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
    JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
    Wilkinson D; Windfeld K; Colding-Jørgensen E
    Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET).
    Lang FM; Mo Y; Sabbagh M; Solomon P; Boada M; Jones RW; Frisoni GB; Grimmer T; Dubois B; Harnett M; Friedhoff SR; Coslett S; Cummings JL
    Alzheimers Dement (N Y); 2021; 7(1):e12136. PubMed ID: 34095437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms.
    Bernard K; Gouttefangeas S; Bretin S; Galtier S; Robert P; Holthoff-Detto V; Cummings J; Pueyo M
    Alzheimers Dement (N Y); 2019; 5():231-240. PubMed ID: 31297437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease.
    Maher-Edwards G; Watson C; Ascher J; Barnett C; Boswell D; Davies J; Fernandez M; Kurz A; Zanetti O; Safirstein B; Schronen JP; Zvartau-Hind M; Gold M
    Alzheimers Dement (N Y); 2015 Jun; 1(1):23-36. PubMed ID: 29854923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
    Dubois B; López-Arrieta J; Lipschitz S; Doskas T; Spiru L; Moroz S; Venger O; Vermersch P; Moussy A; Mansfield CD; Hermine O; Tsolaki M;
    Alzheimers Res Ther; 2023 Feb; 15(1):39. PubMed ID: 36849969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
    Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
    Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
    Monteiro C; Toth B; Brunstein F; Bobbala A; Datta S; Ceniceros R; Sanabria Bohorquez SM; Anania VG; Wildsmith KR; Schauer SP; Lee J; Dolton MJ; Ramakrishnan V; Abramzon D; Teng E;
    Neurology; 2023 Oct; 101(14):e1391-e1401. PubMed ID: 37643887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
    Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
    Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.